Clinique Neuro-Outaouais, Gatineau, QC, Canada.
Front Immunol. 2020 Sep 17;11:564925. doi: 10.3389/fimmu.2020.564925. eCollection 2020.
Since the onset of the COVID-19 pandemic in the fall of 2019 over 4 million people have been infected and over 280,000 have died (1). Information about the SARS-CoV2 virus is evolving rapidly. At this time there are no interventions proven to be effective for cases infected with SARS-CoV2. Current knowledge about the clinical and laboratory manifestations of COVID-19 infection is reviewed and combined with knowledge about the immunopathogenic mechanisms of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV1) and Middle East Respiratory Syndrome (MERS) to formulate theories and suggest possible therapeutic interventions. SARS-CoV2 immunopathogenic mechanisms vary from immunosuppression that initially enables viral escape to a hyperinflammatory immune response. Ultimately therapeutic intervention will be phase dependent.
自 2019 年秋季 COVID-19 大流行爆发以来,已有超过 400 万人感染,超过 28 万人死亡(1)。有关 SARS-CoV2 病毒的信息正在迅速发展。目前,尚无针对 SARS-CoV2 感染病例的有效干预措施。目前正在对 COVID-19 感染的临床和实验室表现进行综述,并结合对严重急性呼吸系统综合征冠状病毒(SARS-CoV1)和中东呼吸系统综合征(MERS)的免疫发病机制的认识,提出理论并提出可能的治疗干预措施。SARS-CoV2 的免疫发病机制从最初使病毒逃逸的免疫抑制到过度炎症反应。最终的治疗干预将取决于阶段。